ARS Pharmaceuticals stock
SPRYNASDAQARS Pharmaceuticals, Inc., HealthcareISIN US82835W1080
33Score 33 out of 100, Weak
Price and trend
39 / 100
Price history
−57% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 46% below it.
Since October 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 71% below its 52-week high. Largest decline in 6 years: 96% (March 2021 to November 2026).
Chart figures for advanced users
- SMA 50$4.11
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.07
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.65
- The lowest closing price of the last twelve months.
- Resistance$13.06
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ARS Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $383.01M, is number 266 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $84.28M (down 5.5% year on year) and a loss of $171.3M.
- For fiscal 2026, analysts expect on average revenue of $128.59M (up 52.6%) and adjusted earnings per share of −$1.79.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 665 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 97.8% a year since 2021, Biotechnology median 19.7%.Growth 59
Weaknesses
- DilutionShare count up 184% since 2020.Capital allocation 18
- Loss-makingLoss of $199.87M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 57% over the last 12 months.Momentum 20
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 30 to 33.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 16% on the same quarter a year earlier. Revenue has grown strongly since 2021, at around 98% per year. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 76%, operating −213%, net −203%. Last 12 months: net −100%. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 8 Mar 2027in 116 days
- Last reported
- 5 Nov 2026EPS reported −$0.36 (expected −$0.31)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.790.0%
- Revenue
- $128.59M0.0%
- Earnings per share
- −$0.820.0%
- Revenue
- $187.11M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −6.6%Second-half 2026 spending is expected at $100 million to $110 million (cash SG&A down more than 40%), market share is expected to rise steadily rather than suddenly, interim data now in the first quarter of 2027.
“As a result, total cash-based SG&A and R&D expenses for the second half of 2026 are expected to be in the range of $100 million-$110 million, driven by a more than 40% reduction in cash-based SG&A expenses from the first half of 2026. Importantly, we expect this spending trend to continue throughout 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $283,550 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at ARS Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Lyell ImmunopharmaLYEL $414.51M33
- Contineum TherapeuticsCTNM $413.46M35
- CorMedixCRMD $413.1M59
- X4 PharmaceuticalsXFOR $408.67M37
- NeurogeneNGNE $396.64M34
- AlectorALEC $391.55M71
- ProKidneyPROK $379.97M27
- C4 TherapeuticsCCCC $379.51M35
ETFs that hold ARS Pharmaceuticals
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Show 4 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.19B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.